Elevai Labs, Inc. Common Stock (ELAB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Elevai Labs, Inc. Common Stock stock (ELAB) is currently trading at $2.89. Elevai Labs, Inc. Common Stock PS ratio (Price-to-Sales) is 6.67. WallStSmart rates ELAB as Sell.
- ELAB PE ratio analysis and historical PE chart
- ELAB PS ratio (Price-to-Sales) history and trend
- ELAB intrinsic value — DCF, Graham Number, EPV models
- ELAB stock price prediction 2025 2026 2027 2028 2029 2030
- ELAB fair value vs current price
- ELAB insider transactions and insider buying
- Is ELAB undervalued or overvalued?
- Elevai Labs, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- ELAB Piotroski F-Score and Altman Z-Score
- ELAB analyst price target and Smart Rating
Elevai Labs, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Elevai Labs, Inc. Common Stock (ELAB) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Elevai Labs, Inc. Common Stock (ELAB) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Elevai Labs, Inc. Common Stock (ELAB) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -45.80%, a shrinking business
Very low institutional interest at 0.05%
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 6.7x annual revenue
Supporting Valuation Data
Elevai Labs, Inc. Common Stock (ELAB) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.22) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (6.67) suggest expensive pricing. Growth concerns include Revenue Growth at -45.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -76.20%, Operating Margin at -752.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -76.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -45.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ELAB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ELAB's Price-to-Sales ratio of 6.67x trades at a deep discount to its historical average of 164.42x (70th percentile). The current valuation is 100% below its historical high of 5318.01x set in Dec 2023, and 7311% above its historical low of 0.09x in Nov 2024. Over the past 12 months, the PS ratio has expanded from ~0.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Elevai Labs, Inc. Common Stock (ELAB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Elevai Labs, Inc. Common Stock operates as a stable business with moderate growth and solid fundamentals. Revenue reached 285,950 with 46% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue contracted 46% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Elevai Labs, Inc. Common Stock.
Bottom Line
Elevai Labs, Inc. Common Stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Elevai Labs, Inc. Common Stock(ELAB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Elevai Labs, Inc. (Ticker: ELAB) is a cutting-edge technology company focused on revolutionizing artificial intelligence and machine learning applications. With its advanced data analytics platforms, Elevai Labs facilitates enhanced decision-making across key sectors, particularly in healthcare and finance, enabling organizations to extract actionable insights from complex datasets. Positioned at the forefront of the rapidly evolving tech landscape, the company is well-equipped to capitalize on emerging trends, thereby delivering significant value and operational efficiency to its clients and stakeholders.